ArticleInternational journal of oncology2013
SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2.
Article in International journal of oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 67 citations in OpenAlex.
- Sirtuin family in lung adenocarcinoma.Discover oncology · 2025Review
- Sirtuin insights: bridging the gap between cellular processes and therapeutic applications.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery Process.Journal of medicinal chemistry · 2024Review
- Association of sirtuins (SIRT1-7) with lung and intestinal diseases.Molecular and cellular biochemistry · 2022Review
- CRIF1 promotes the progression of non-small-cell lung cancer by SIRT3- mediated deacetylation of PYCR1.Journal of molecular histology · 2022Article
- Glycyrrhizic acid exhibits strong anticancer activity in colorectal cancer cells via SIRT3 inhibition.Bioengineered · 2022Article
- Small Molecule Regulators Targeting NADCurrent medicinal chemistry · 2022Article
- Constructing a signature based on the SIRT family to help the prognosis and treatment sensitivity in glioma patients.Frontiers in genetics · 2022Article
- The Double-Edged Sword of SIRT3 in Cancer and Its Therapeutic Applications.Frontiers in pharmacology · 2022Review
- Sirt3 Regulates Response to Oxidative Stress by Interacting with BER Proteins in Colorectal Cancer.Genetics research · 2022Article
- Article
- NMNAT1 Is a Survival Factor in Actinomycin D-Induced Osteosarcoma Cell Death.International journal of molecular sciences · 2021Article
- Advances in NAD-Lowering Agents for Cancer Treatment.Nutrients · 2021Review
- Tubeimoside I Ameliorates Myocardial Ischemia-Reperfusion Injury through SIRT3-Dependent Regulation of Oxidative Stress and Apoptosis.Oxidative medicine and cellular longevity · 2021Article
- Effects of Sirt3‑autophagy and resveratrol activation on myocardial hypertrophy and energy metabolism.Molecular medicine reports · 2020Article
- SIRT3 promotes the invasion and metastasis of cervical cancer cells by regulating fatty acid synthase.Molecular and cellular biochemistry · 2020Article
- Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target.Theranostics · 2020Review
- Sirtuin 3, Endothelial Metabolic Reprogramming, and Heart Failure With Preserved Ejection Fraction.Journal of cardiovascular pharmacology · 2019Review
- Article
- The sirtuin family in cancer.Cell cycle (Georgetown, Tex.) · 2019Article
Corrections and comments
- Retraction · 2023-04-07Author Unresponsive · Duplication of/in Image · Unreliable Results and/or Conclusions · · see also: https://pubpeer.com/publications/F67ECCCCE34F72B86682B829DB1DB0
- Retracted
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of death worldwide and associated with dismal prognoses. As a major mitochondrial deacetylase, SIRT3 regulates the activity of enzymes to coordinate global shifts in cellular metabolism and has important implications for tumor growth. Its role as a tumor suppressor or an oncogene in lung cancer is unclear, especially in non-small cell lung carcinoma (NSCLC). To identify the mechanism of SIRT3-interacting proteins, we performed a yeast two-hybrid screen using a human lung cDNA library. One of the positive clones encoded the full-length cDNA of the nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) gene and the interaction between SIRT3 and NMNAT2 was identified. The interaction on growth, proliferation, apoptosis of NSCLC cell lines, and energy metabolism related to SIRT3 were investigated. Screening from the library resulted in NMNAT2 gene. We found that NMNAT2 interacts with SIRT3 both in vitro and in vivo; SIRT3 binds to NMNAT2 deacetylating it. Downregulation of SIRT3 inhibited acetylation of NMNAT2 and NAD+ synthesis activity of the enzyme. Low expression of SIRT3 significantly inhibited mitotic entry, growth and proliferation of NSCLC cell lines and promoted apoptosis, which was related to energy metabolism involving in the interaction between SIRT3 and NMNAT2. Taken together, our results strongly suggest that the binding of SIRT3 with NMNAT2 is a novel regulator of cell proliferation and apoptosis in NSCLC cell lines, implicating the interaction between SIRT3 and NMNAT2, energy metabolism associated with SIRT3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.